Compare XAIR & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XAIR | AZTR |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.5M |
| IPO Year | 2015 | 2023 |
| Metric | XAIR | AZTR |
|---|---|---|
| Price | $3.08 | $0.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $4.00 |
| AVG Volume (30 Days) | 131.0K | ★ 1.1M |
| Earning Date | 06-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,679,000.00 | N/A |
| Revenue This Year | $122.00 | N/A |
| Revenue Next Year | $58.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 107.26 | N/A |
| 52 Week Low | $0.33 | $0.10 |
| 52 Week High | $8.19 | $1.09 |
| Indicator | XAIR | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 57.54 |
| Support Level | $0.55 | $0.17 |
| Resistance Level | $7.09 | $0.23 |
| Average True Range (ATR) | 0.42 | 0.01 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 1.47 | 53.56 |
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.